-
Advanced and Metastatic Breast Cancer
846
us
1
1.0
1.0
Clinical Case
0
1
Pathology & Lab Medicine2023-03-13 20:00:00
Are you up to date with the latest guidance and best practices in breast cancer human epidermal growth factor receptor 2 (HER2) testing? Learn more here!
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-09 19:00:00
Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Lung Cancer
5000186
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-02-27 19:00:00
Do you know the latest information on immunotherapy for the management of non-small cell lung cancer (NSCLC)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Biologic Therapy
5000033
global
1
0.25
9
0.25
0.25
Clinical Review
0
1
Hematology-Oncology2023-02-22 19:00:00
Did you know? Immunotherapy is now being used for the neoadjuvant and adjuvant treatment of solid tumors -- find out more here!
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Noncolorectal Gastrointestinal Cancer
5005286
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-02-21 19:00:00
Are you up to date on the latest data on the management of cholangiocarcinoma and how it applies to clinical practice?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Pancreatic Cancer
669
global
1
1.25
9
1.25
1.25
Roundtable
0
1
Hematology-Oncology2023-02-07 19:00:00
Did you know that pancreatic cancer remains a deadly condition that is often not discovered until the metastatic stage?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
COVID-19
6012524
global
1
0.25
9
0.25
2
0.25
3
0.25
8
0.25
0.25
Clinical Brief
0
1
Cardiology2023-03-16 20:00:00
A recent study analyzes the rate at which acute cardiac events occur in COVID-19 hospital admissions.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Advanced and Metastatic Breast Cancer
846
us
1
1.0
1.0
Clinical Case
0
1
Pathology & Lab Medicine2023-03-13 20:00:00
Are you up to date with the latest guidance and best practices in breast cancer human epidermal growth factor receptor 2 (HER2) testing? Learn more here!
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-09 19:00:00
Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Lung Cancer
5000186
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-02-27 19:00:00
Do you know the latest information on immunotherapy for the management of non-small cell lung cancer (NSCLC)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Biologic Therapy
5000033
global
1
0.25
9
0.25
0.25
Clinical Review
0
1
Hematology-Oncology2023-02-22 19:00:00
Did you know? Immunotherapy is now being used for the neoadjuvant and adjuvant treatment of solid tumors -- find out more here!
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Noncolorectal Gastrointestinal Cancer
5005286
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-02-21 19:00:00
Are you up to date on the latest data on the management of cholangiocarcinoma and how it applies to clinical practice?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Pancreatic Cancer
669
global
1
1.25
9
1.25
1.25
Roundtable
0
1
Hematology-Oncology2023-02-07 19:00:00
Did you know that pancreatic cancer remains a deadly condition that is often not discovered until the metastatic stage?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
Genomic Medicine
3029493
global
1
0.25
2
0.25
8
0.25
0.25
Clinical Brief
0
1
Pediatrics2023-02-02 19:00:00
A new study demonstrates genetic abnormalities in a minority of cases of sudden unexplained death in pediatrics.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Lung Cancer
5000186
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Pathology & Lab Medicine2023-01-30 19:00:00
How do you approach testing and treatment of patients with EGFR mutations? Join here for a multidisciplinary perspective.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Acute Leukemia
5005273
global
1
0.75
9
0.75
2
0.75
3
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-01-29 19:00:00
What’s new in FLT3 acute myeloid leukemia (AML)? Join to hear a panel of experts discuss how they use FLT3 inhibitors in patients with AML.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Lung Cancer
5000186
global
1
0.25
9
0.25
2
0.25
3
0.25
8
0.25
0.25
Clinical Brief
0
1
Family Medicine/Primary Care2023-01-26 19:00:00
A new study examines the 10-year lung cancer survival rate for adults who receive prompt surgery for screening-detected stage I lung cancer.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Ovarian Cancer
839
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-01-19 19:00:00
Three case studies illustrate the use of poly(ADP-ribose) polymerase (PARP) inhibitors in the management of ovarian cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Acute Leukemia
5005273
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-01-17 19:00:00
Catch up on the biggest news in AML, MDS, and MPNs from the 2022 Winter Hematology meeting.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Melanoma
65
global
1
0.25
9
0.25
0.25
Clinical Review
0
1
Hematology-Oncology2023-01-12 19:00:00
Did you know that melanoma has more somatic mutations than any other cancer type?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Cardiovascular Risk Management
3029460
global
1
0.25
9
0.25
2
0.25
8
0.25
0.25
Clinical Brief
0
1
Cardiology2023-01-12 19:00:00
A new study analyzes high levels of lipoprotein(a) with the association of cardiovascular risk.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Endometrial Cancer
3003432
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-01-09 19:00:00
Do you know the best management strategies and the latest clinical data for advanced endometrial cancer (EC)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Multiple Myeloma
1166
global
1
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-12-29 19:00:00
Did you know that B-cell maturation antigen (BCMA) is heavily present on myeloma cells, meaning that BCMA-targeted therapy could help slow the growth of myeloma?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Chronic Lymphocytic Leukemia
1551
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-12-29 19:00:00
Did you know that the second-generation Bruton tyrosine kinase (BTK) inhibitors will likely be the new standard of care when used as monotherapy?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
